Загрузка...
Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review
Cystic fibrosis (CF) is a rare, progressive, multi-organ genetic disease. Ivacaftor, a small-molecule CF transmembrane conductance regulator modulator, was the first medication to treat the underlying cause of CF. Since its approval, real-world clinical experience on the use of ivacaftor has been do...
Сохранить в:
| Опубликовано в: : | J Clin Med |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8038673/ https://ncbi.nlm.nih.gov/pubmed/33917386 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10071527 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|